Founding Organizations:

In this accredited CME presentation, supported by Medical Education Resources and the Chronic Liver Disease Foundation through an independent educational grant, leading experts provide a comprehensive, up-to-date exploration of Metabolic Steatotic Liver Disease (MASLD), formerly known as NAFLD and NASH. Covering everything from diagnosis to therapy, the session emphasizes the clinical utility of non-invasive tests (NITs) such as FIB-4, transient elastography (FibroScan), ELF score, and MRI elastography to stage fibrosis without liver biopsy. With a global prevalence affecting nearly one-third of the population, MASLD represents a growing public health challenge—particularly among individuals with type 2 diabetes and obesity. The speaker outlines a practical, stepwise approach to risk stratification, population-based screening, and patient counseling strategies to drive behavioral change. He also discusses the evolving role of lifestyle interventions, GLP-1 receptor agonists, and newly approved resmetirom (Rezdiffra), the first FDA-approved therapy for NASH with moderate to advanced fibrosis. Learn how to identify high-risk patients, initiate effective management plans, and use non-invasive tools to track progression and response to therapy. This session is essential for gastroenterologists, hepatologists, and primary care providers managing patients with fatty liver disease in clinical practice.